Skip to main content

The Extraordinary General Assembly of Farmaindustria held in Madrid has appointed Antoni Esteve as the new president of the Association. Thus, in compliance with the Farmaindustria bylaws that establish the presidency must alternate between companies with foreign and national capital, Esteve will take over from Elvira Sanz for the coming two years.

The new Executive Committee and Board of Directors were also constituted at the Assembly. The group also analyzed the current situation of the pharmaceutical industry in Spain, showing that an R&D-intensive sector like this one can't grow less than it is in Spain, highlighting the need to reach an economic situation that allows for the incorporation of therapeutic innovations.

For Antoni Esteve, the main challenge will be to ensure patients have access to innovative, quality drugs and to the treatments they need. Thus, in his opinion, the pharmaceutical industry must work to “search for new financing formulas and policies that guarantee the sustainability of healthcare systems in ways that are compatible with the incorporation of the most avant-garde therapies.”

Furthermore, the new president of Farmaindustria sent a message that will be key to his presidency: innovations will be seen as investment, not expenditure, as he believes they are an inalienable part of our society. 

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.